Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 27 August 2014 | By Alexander Gaffney, RAC,
A new final guidance document issued by the US Food and Drug Administration (FDA) aims to make it easier to develop in vitro diagnostic devices (IVDs) intended to act as microbiological or medical countermeasures.
The guidance document, Highly Multiplexed Microbiological/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices, is specifically aimed at those IVDs which are intended to simultaneously detect 20 or more pathogens extracted from a single sample. Those IVDs, known as highly multiplexed diagnostic devices (HMDDs), are meant to test multiple targets "through a common process of specimen preparation, amplification and/or detection, and result interpretation," FDA explains in its guidance.
Such devices have great utility as medical countermeasures, especially when health professionals need to quickly determine which disease or pathogen might be affecting patients—and which are not.
While some of these devices are never given full approvals, and are instead given emergency use authorizations (EUAs) under the Pandemic and All-Hazards Preparedness and Reauthorization Act(PAHPRA), they are also approved under normal device review procedures as well. FDA's guidance is meant to explain the studies necessary to obtain market clearance [i.e. a 510(k) or de novo notification].
As with IVD's in general, FDA notes that HMDDs are not without risk. False positive results, false negative results, failure of the device to perform as indicated or improper interpretation of results can all present risks to human health. Such risks should be quantified and, to the extent possible, controlled.
FDA's guidance describes some of the basic elements of what each FDA application should include. For example, the guidance calls for companies to describe:
The guidance also contains an extensive section on performance characteristics, which should be established by properly designed studies. The section goes into the pre-analytical factors (such as specimen characteristics and quality controls), the analytical performance and specificity of the device, the precision and reproducibility of the device, the use of comparators, software used in the device, the design of clinical studies and the presentation of data.
The draft of the guidance document was published by FDA in November 2012.
Highly Multiplexed Microbiological/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices (FR)
Tags: HMDD, IVD, Nuclear Acid Based Diagnostic Devices, Guidance Document, Guidance, Final Guidance, Medical Countermeasure, Microbiological Countermeasure
Regulatory Focus newsletters
All the biggest regulatory news and happenings.